Incretin therapy calibrated to your titration step — injectable or fully needle-free.
How this category works
These medications work by slowing down how fast your stomach empties, helping your brain recognize when you're full, and improving how your body processes sugar. Your doctor gradually increases your dose over 12 weeks to build up that appetite control while giving your stomach time to adjust, preventing issues like nausea or an upset stomach.
Showing 3 protocols
Dual GIP / GLP-1 incretin protocol for sustained fat loss.
GLP-1 receptor agonist protocol for appetite and glycemic control.
Needle-free dual incretin tablet for plateau breakthrough.
Model your 12-week GLP-1 dose ramp to balance metabolic appetite suppression against gastrointestinal tolerability.
Clinically proven outcomes
Every protocol is physician-directed, continually titrated, and compounded to certified USP standards.
Clinical education
Semaglutide works on the GLP-1 receptor alone. Tirzepatide adds GIP, a second appetite and insulin pathway, which is why average weight change in head-to-head trials runs meaningfully higher on the dual agonist at comparable tolerability.
Monotherapy pens contain the peptide and nothing else. Compounding lets a physician add Glycine and B12 to the same vial or tablet, supporting muscle protein synthesis and energy through a sustained calorie deficit instead of losing lean tissue alongside fat.
Brand pens step in fixed increments. A compounded formulation is dosed to the exact milligram your titration needs, so nausea can be managed by half-steps rather than pausing treatment or dropping a full level.
Calibrated Satiety Signaling
Lean Mass Preservation